# ESKETamine for FIBromyalgia Treatment

> **NCT04436250** · NA · TERMINATED · sponsor: **Grand Hôpital de Charleroi** · enrollment: 23 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** Active comparator
- **DRUG:** S-Ketamine Low dose
- **DRUG:** S-Ketamine High dose

## Key facts

- **NCT ID:** NCT04436250
- **Lead sponsor:** Grand Hôpital de Charleroi
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-10
- **Primary completion:** 2024-08-31
- **Final completion:** 2024-09-30
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Lack of recruitment.
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04436250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04436250, "ESKETamine for FIBromyalgia Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04436250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*